Teva and Immunai partner to improve clinical decision making
The companies will focus on mechanisms of action, dose selection and biomarker analyses
Read More
Tag: immuno-oncology
Orion and Alligator reveal second stage of immuno-oncology research collaboration
Second study will develop a bispecific antibody with potential applications in solid tumours
Read More
Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
Preparations come on the heels of positive results from the Phase II ARC-7 study
Read More
Human trials for world’s first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
Read More
Immodulon, Champalimaud Foundation team up on ‘difficult to treat’ cancers
Collaboration will explore experimental treatment IMM-101 in combination with other therapies in advanced cancers
Read More
Gilead strikes $4.9bn deal to buy Forty Seven
The acquisition is set to strengthen Gilead’s immuno-oncology research and development portfolio with drugs such as Forty Seven’s magrolimab.
Read More
Bicycle, Roche collab for immuno-oncology therapies
Under the terms of the agreement, the companies will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
Read More
AZ, Forty Seven to test triple immunotherapy combo for lymphoma
5F9 will be tested in combination with rituximab and Calquence (acalabrutinib) for diffuse large B-cell lymphoma.
Read More
AZ finds lack of lung cancer info available for patients
Available information is often outdated and sometimes inaccurate.
Read More
Grey Wolf completes £10m funding for immuno-oncology therapies
Grey Wolf Therapeutics has completed a £10 million series A financing to fund development of immuno-oncology therapies to increase tumour visibility.
Read More
European Commission approves Opdivo for advanced renal cell carcinoma
The European Commission has approved Bristol-Myers Squibb’s Opdivo in combination with low-dose Yervoy for first-line treatment of patients with intermediate and poor risk advanced renal cell carcinoma (RCC).
Read More
Regeneron and Sanofi restructure immuno-oncology collaboration
Regeneron and Sanofi have restructured their global immuno-oncology discovery and development agreement for new immuno-oncology cancer treatments, with Sanofi set to pay $462 million to end the collaboration early.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
